$PGEN

Thomasian Harry Jr. sold $183K of PGEN

Thomasian Harry Jr. (Chief Financial Officer) sold 41,884 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.18M total) on 2026-05-28.

Original reporting
SEC EDGAR · Thomasian Harry Jr.
Published Jun 1, 2026, 8:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

This provides a datapoint on insider behavior (open-market sale) but does not introduce new company fundamentals like trial results, guidance, financing, or contracts.

02

Market read

Traders may monitor for follow-through selling pressure, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Insider sales often occur for tax/financial planning; without context on total compensation, prior sales, or remaining holdings, signal strength is weak.

Relevance 6/10Novelty 6/10Timing: after SEC filing (filed 2026-06-01) for a sale executed 2026-05-28

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure by Precigen’s CFO.

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

SEC Form 4 shows CFO Harry Jr. sold 41,884 shares of Precigen at $4.36/share, disclosing direct insider selling activity.

Expected impact

Low near-term impact; any move is likely sentiment-driven and limited unless accompanied by other news.

Evidence & confidence

The filing is an ownership-change disclosure with no new operating/financial information; also explicitly notes no 10b5-1 plan, which can raise attention but still lacks a direct causal catalyst.

Market effects

Limited read-across to biotech/clinical-stage sentiment; insider selling is company-specific and typically not sector-wide.

None indicated; US-listed microcap/small-cap style flow effects only.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing; absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • PRECIGEN, INC.

    Company whose CFO reported an open-market sale of shares via SEC Form 4.

  • Thomasian Harry Jr.

    Precigen CFO who sold 41,884 shares at $4.36/share.

Related articles

$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e